Dr. Sheikh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
711 Canton Rd NE
Ste 300
Marietta, GA 30060Phone+1 678-741-5000Fax+1 678-819-4280
Education & Training
- Stony Brook Medicine/University HospitalFellowship, Gastroenterology, 1994 - 1997
- Baylor College of MedicineResidency, Internal Medicine, 1991 - 1994
- Aga Khan Medical CollegeClass of 1988
Certifications & Licensure
- GA State Medical License 2006 - 2025
- AL State Medical License 1998 - 2012
- PA State Medical License 1996 - 1998
- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2011-2013
Clinical Trials
- Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease Start of enrollment: 2013 Sep 01
- Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis Start of enrollment: 2014 Mar 27
- Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis Start of enrollment: 2014 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 17 citationsImprovements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steat...Zobair M. Younossi, Maria Stepanova, Mazen Noureddin, Kris V. Kowdley, Simone I. Strasser
Hepatology Communications. 2021-05-12 - 492 citationsAll-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III StudyDavid R. Nelson, James N. Cooper, Jacob Lalezari, Eric Lawitz, Paul J. Pockros
Hepatology. 2015-04-01 - 155 citationsA randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.Stephen A. Harrison, Zachary Goodman, Abdul Jabbar, Ravi Vemulapalli, Ziad Younes
Journal of Hepatology. 2020-05-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: